https://www.selleckchem.com/pr....oducts/ch5424802.htm
2.15 cells (P less then 0.05). EGR3 was a target of miRNA-210, which was down-regulated in the liver tissues of HBV-associated cirrhosis and liver cancer, and in HepG2 and HepG2.2.15 cells (P less then 0.05). Silencing of miRNA-210 increased the mRNA and protein expression of EGR3 (P less then 0.05). Silencing of EGR3 reversed the anti-tumor effect of miRNA-210 inhibitor on HepG2 and HepG2.2.15 cells (P less then 0.05). CONCLUSIONS Silencing of miRNA-210 inhibits the progression of liver cancer and HBV-associated liver cancer
Like
Comment
Share
